Evidence map›Paper›PMID 24349464›Full record

ArticlePloS one2013

ADP protects cardiac mitochondria under severe oxidative stress.

Niina Sokolova, Shi Pan, Sarah Provazza, Gisela Beutner, Marko Vendelin, Rikke Birkedal, Shey-Shing Sheu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Differential CaFrontiers in synaptic neuroscience · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Total Matrix CaFrontiers in physiology · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Niina SokolovaInstitute of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Shi PanCenter for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
Sarah ProvazzaDepartment of Pharmacology and Physiology, University of Rochester, Rochester, New York, United States of America.
Gisela BeutnerDepartment of Pharmacology and Physiology, University of Rochester, Rochester, New York, United States of America.
Marko VendelinInstitute of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Rikke BirkedalInstitute of Cybernetics, Tallinn University of Technology, Tallinn, Estonia.
Shey-Shing SheuDepartment of Pharmacology and Physiology, University of Rochester, Rochester, New York, United States of America ; Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
Tallinn University of Technology · EEUniversity of Rochester · USThomas Jefferson University · US

Funding

Ca2+ and ROS Crosstalk Signaling in Cardiac MitochondriaR01HL093671 · NHLBI · UNIVERSITY OF ROCHESTER · PI SHEU, SHEY-SHING · 2010 to 2023
$5.1M
MYOCARDIAL CA2+ TRANSPORT AND METABOLISMR01HL033333 · NHLBI · UNIVERSITY OF ROCHESTER · PI SHEU, SHEY-SHING · 1985 to 2010
$2.3M
ADP: A Master Regulator for Bioenergetics and Ca2+/ROS Signaling in HeartR21HL110371 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI SHEU, SHEY-SHING · 2011 to 2012
$426k
NHLBI NIH HHS HL-33333NHLBI NIH HHS R01 HL033333NHLBI NIH HHS R01HL-033333NHLBI NIH HHS R01 HL093671NHLBI NIH HHS R01HL-093671NHLBI NIH HHS R21 HL110371NHLBI NIH HHS R21HL-110371Wellcome TrustWellcome Trust 081755
6 · The paper itself

Abstract

ADP is not only a key substrate for ATP generation, but also a potent inhibitor of mitochondrial permeability transition pore (mPTP). In this study, we assessed how oxidative stress affects the potency of ADP as an mPTP inhibitor and whether its reduction of reactive oxygen species (ROS) production might be involved. We determined quantitatively the effects of ADP on mitochondrial Ca(2+) retention capacity (CRC) until the induction of mPTP in normal and stressed isolated cardiac mitochondria. We used two models of chronic oxidative stress (old and diabetic mice) and two models of acute oxidative stress (ischemia reperfusion (IR) and tert-butyl hydroperoxide (t-BH)). In control mitochondria, the CRC was 344 ± 32 nmol/mg protein. 500 μmol/L ADP increased CRC to 774 ± 65 nmol/mg protein. This effect of ADP seemed to relate to its concentration as 50 μmol/L had a significantly smaller effect. Also, oligomycin, which inhibits the conversion of ADP to ATP by F0F1ATPase, significantly increased the effect of 50 μmol/L ADP. Chronic oxidative stress did not affect CRC or the effect of 500 μmol/L ADP. After IR or t-BH exposure, CRC was drastically reduced to 1 ± 0.2 and 32 ± 4 nmol/mg protein, respectively. Surprisingly, ADP increased the CRC to 447 ± 105 and 514 ± 103 nmol/mg protein in IR and t-BH, respectively. Thus, it increased CRC by the same amount as in control. In control mitochondria, ADP decreased both substrate and Ca(2+)-induced increase of ROS. However, in t-BH mitochondria the effect of ADP on ROS was relatively small. We conclude that ADP potently restores CRC capacity in severely stressed mitochondria. This effect is most likely not related to a reduction in ROS production. As the effect of ADP relates to its concentration, increased ADP as occurs in the pathophysiological situation may protect mitochondrial integrity and function.

Indexed as

Oxidative StressAdenosine DiphosphateAnimalsCalciumMaleMiceMitochondria, HeartMyocardial Reperfusion InjuryProton-Translocating ATPasesReactive Oxygen SpeciesAdenosine DiphosphateCalciumProton-Translocating ATPasesReactive Oxygen Species

Identifiers

PMID24349464
PMCPMC3862761
OpenAlexW2091666277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.